Company profile
KEROS THERAPEUTICS, INC.
NASDAQ:KROSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| KER-047 | phase2 | — | 1 | withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05927012 | phase2 | withdrawn | 2023-11-30 | 2025-08-29 | Keros Therapeutics, Inc. | A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia). |
| NCT05975905 | phase2 | terminated | 2023-10-17 | 2025-03-05 | Keros Therapeutics, Inc. | A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study). |
| NCT07704099 | phase2 | recruiting | 2026-09-25 | 2028-08-26 | Keros Therapeutics, Inc. | Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy |
FDA applications (0)
No records yet.